Royalty Pharma plc (Nasdaq: RPRX) announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE